Mortality and resource utilization in surgical versus transcatheter repeat mitral valve replacement: A national analysis.
Nguyen K LeNikhil L ChervuSaad MallickAmulya VadlakondaShineui KimJoanna CurryPeyman BenharashPublished in: PloS one (2024)
In this retrospective cohort study, we noted TMVR to yield similar odds of in-hospital mortality as SMVR, but fewer complications and reduced healthcare expenditures. Moreover, transseptal approaches were associated with lower adjusted mortality, shorter pLOS, but higher cost, relative to the transapical. Our findings suggest that TMVR represent a cost-effective and safe treatment modality for patients requiring redo mitral valve procedures. Nevertheless, future studies examining long-term outcomes associated with SMVR and TMVR in redo mitral valve operations, are needed.
Keyphrases
- mitral valve
- left atrial
- healthcare
- left ventricular
- end stage renal disease
- risk factors
- cardiovascular events
- ejection fraction
- chronic kidney disease
- newly diagnosed
- prognostic factors
- aortic valve replacement
- type diabetes
- patient reported outcomes
- quality improvement
- heart failure
- health insurance
- aortic valve
- health information
- data analysis